These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 22318636

  • 1. Susceptibilities to amphotericin B, fluconazole and voriconazole of Trichosporon clinical isolates.
    Tsai MS, Yang YL, Wang AH, Wang LS, Lu DC, Liou CH, Hsieh LY, Wu CJ, Cheng MF, Shi ZY, Lo HJ.
    Mycopathologia; 2012 Aug; 174(2):121-30. PubMed ID: 22318636
    [Abstract] [Full Text] [Related]

  • 2. Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
    Hazirolan G, Canton E, Sahin S, Arikan-Akdagli S.
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4841-7. PubMed ID: 23877683
    [Abstract] [Full Text] [Related]

  • 3. Species distribution and antifungal susceptibility of 358 Trichosporon clinical isolates collected in 24 medical centres.
    Francisco EC, de Almeida Junior JN, de Queiroz Telles F, Aquino VR, Mendes AVA, de Andrade Barberino MGM, de Tarso O Castro P, Guimarães T, Hahn RC, Padovan ACB, Chaves GM, Colombo AL.
    Clin Microbiol Infect; 2019 Jul; 25(7):909.e1-909.e5. PubMed ID: 30991116
    [Abstract] [Full Text] [Related]

  • 4. Trichosporon asahii causing nosocomial urinary tract infections in intensive care unit patients: genotypes, virulence factors and antifungal susceptibility testing.
    Sun W, Su J, Xu S, Yan D.
    J Med Microbiol; 2012 Dec; 61(Pt 12):1750-1757. PubMed ID: 22956749
    [Abstract] [Full Text] [Related]

  • 5. The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
    Mariné M, Bom VL, de Castro PA, Winkelstroter LK, Ramalho LN, Brown NA, Goldman GH.
    Virulence; 2015 Dec; 6(5):476-86. PubMed ID: 25751127
    [Abstract] [Full Text] [Related]

  • 6. Molecular characterisation and antifungal susceptibility of clinical Trichosporon isolates in India.
    Rastogi V, Honnavar P, Rudramurthy SM, Pamidi U, Ghosh A, Chakrabarti A.
    Mycoses; 2016 Aug; 59(8):528-34. PubMed ID: 27144725
    [Abstract] [Full Text] [Related]

  • 7. Multiple species of Trichosporon produce biofilms highly resistant to triazoles and amphotericin B.
    Iturrieta-González IA, Padovan AC, Bizerra FC, Hahn RC, Colombo AL.
    PLoS One; 2014 Aug; 9(10):e109553. PubMed ID: 25360765
    [Abstract] [Full Text] [Related]

  • 8. Isolation and antifungal susceptibility testing of Trichosporon asahii in Ceará, Brazil.
    Menezes EA, Marinho JA, Angelo MR, Cunha Mda C, Cunha FA, Vasconcelos Júnior AA.
    Rev Inst Med Trop Sao Paulo; 2012 Aug; 54(1):1-3. PubMed ID: 22370746
    [Abstract] [Full Text] [Related]

  • 9. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii.
    Li H, Lu Q, Wan Z, Zhang J.
    Int J Antimicrob Agents; 2010 Jun; 35(6):550-2. PubMed ID: 20202797
    [Abstract] [Full Text] [Related]

  • 10. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
    Uzun O, Arikan S, Kocagöz S, Sancak B, Unal S.
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
    [Abstract] [Full Text] [Related]

  • 11. MALDI-TOF MS characterisation, genetic diversity and antifungal susceptibility of Trichosporon species from Iranian clinical samples.
    Ahangarkani F, Ilkit M, Vaseghi N, Zahedi N, Zomorodian K, Khodavaisy S, Afsarian MH, Abbasi K, de Groot T, Meis JF, Badali H.
    Mycoses; 2021 Aug; 64(8):918-925. PubMed ID: 33998718
    [Abstract] [Full Text] [Related]

  • 12. Genotyping, extracellular compounds, and antifungal susceptibility testing of Trichosporon asahii isolated from Mexican patients.
    Montoya AM, Sánchez González A, Palma-Nicolás JP, Gómez-Treviño A, González JG, González GM.
    Med Mycol; 2015 Jun; 53(5):505-11. PubMed ID: 25980003
    [Abstract] [Full Text] [Related]

  • 13. Genotype analysis based on intergenic spacer 1 sequences of Trichosporon asahii collected in Taiwan.
    Yang YL, Liu YW, Chen HT, Tsai MS, Chu WL, Lo HJ.
    Med Mycol; 2013 Nov; 51(8):880-3. PubMed ID: 23768241
    [Abstract] [Full Text] [Related]

  • 14. Invasive Infections Due to Trichosporon: Species Distribution, Genotyping, and Antifungal Susceptibilities from a Multicenter Study in China.
    Guo LN, Yu SY, Hsueh PR, Al-Hatmi AMS, Meis JF, Hagen F, Xiao M, Wang H, Barresi C, Zhou ML, de Hoog GS, Xu YC.
    J Clin Microbiol; 2019 Feb; 57(2):. PubMed ID: 30463892
    [Abstract] [Full Text] [Related]

  • 15. Epidemiology and Antifungal Susceptibility of Infections Caused by Trichosporon Species: An Emerging Non-Candida and Non-Cryptococcus Yeast Worldwide.
    Singh S, Capoor MR, Varshney S, Gupta DK, Verma PK, Ramesh V.
    Indian J Med Microbiol; 2019 Feb; 37(4):536-541. PubMed ID: 32436877
    [Abstract] [Full Text] [Related]

  • 16. Implication of efflux pumps and ERG11 genes in resistance of clinical Trichosporon asahii isolates to fluconazole.
    Abbes S, Sellami H, Neji S, Trabelsi H, Makni F, Ayadi A.
    J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33688802
    [Abstract] [Full Text] [Related]

  • 17. Genotyping and antifungal drug susceptibility of Trichosporon asahii isolated from Chinese patients.
    Xia Z, Yang R, Wang W, Cong L.
    Mycopathologia; 2012 Mar; 173(2-3):127-33. PubMed ID: 21979867
    [Abstract] [Full Text] [Related]

  • 18. Molecular and antifungal susceptibility study on trichosporonemia and emergence of Trichosporon mycotoxinivorans as a bloodstream pathogen.
    Dabas Y, Xess I, Kale P.
    Med Mycol; 2017 Jul 01; 55(5):518-527. PubMed ID: 27816903
    [Abstract] [Full Text] [Related]

  • 19. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P.
    Int J Antimicrob Agents; 2008 Dec 01; 32(6):511-4. PubMed ID: 18790613
    [Abstract] [Full Text] [Related]

  • 20. Biofilm formation and antifungal susceptibility of Trichosporon asahii isolates from Mexican patients.
    Montoya AM, Elizondo-Zertuche M, Treviño-Rangel RJ, Becerril-García M, González GM.
    Rev Iberoam Micol; 2018 Dec 01; 35(1):22-26. PubMed ID: 29287630
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.